This article is more than 5 years old. Information may no longer be current.

Inspire reports 48% increase in revenues in third quarter of 2006

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DURHAM, N.C. — Inspire Pharmaceuticals Inc. reported revenue totaling $9.7 million in the third quarter of 2006, a 48% increase compared to the previous year, the company announced.

The increased revenue was entirely generated from co-promotion activities. In particular, net sales of Elestat (epinastine HCl ophthalmic solution) increased 20% to $5.4 million, and net sales of Restasis (cyclosporine ophthalmic emulsion) increased 109% to $4.3 million, according to a press release from Inspire.

Overall, the company reported a net loss of $7.2 million, or $0.17 per share, vs. a net loss of $6.8 million, or $0.16 per share, for the third quarter of 2005, according to the release.